Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice some reduction in appetite within the first one to two weeks of starting Mounjaro, though the full effect builds gradually over several months as the dose increases. Mounjaro (tirzepatide) works by activating two gut-hormone receptors (GIP and GLP-1) that signal fullness to the brain and slow how quickly your stomach empties. Because it's a prescription-only medicine, a prescriber assesses your suitability before treatment begins; the timeline you experience will depend on your individual response and how titration proceeds.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
For many people, something shifts in the first seven to fourteen days, meals feel like too much, snacks lose their pull, and portion sizes that felt normal suddenly seem excessive. This can happen even at 2.5mg, the starting dose whose primary job is letting your body adjust rather than delivering peak effect. The appetite signal at this stage is real, but it is often modest compared to what comes later.
What's happening biologically is that tirzepatide is binding to GIP and GLP-1 receptors in the gut and brain almost immediately after the first injection. The gut slows gastric emptying, so food lingers longer in the stomach. Satiety hormones rise. The brain receives a quieter hunger signal. You can read more about the mechanism on our overview of how Mounjaro affects appetite.
That said, the first few weeks can also bring nausea and other gastrointestinal effects that are sometimes mistaken for appetite suppression. True appetite suppression is a reduction in hunger and desire to eat, and if you want a deeper look at whether tirzepatide genuinely suppresses appetite and how that process works, we cover it in full on a dedicated page. The NHS tirzepatide page covers common side effects and what to watch for.
Tirzepatide is titrated slowly (typically stepping up every four weeks) and the appetite-suppressing effect genuinely intensifies at each rung. The 5mg dose tends to feel meaningfully different from 2.5mg. The 7.5mg and 10mg doses often bring a clearer, more consistent reduction in hunger. At 12.5mg and 15mg, many people describe barely thinking about food between meals.
This matters because early-stage results (particularly in the first month) are not the ceiling. Patients who feel only mild appetite suppression at 2.5mg sometimes conclude the medicine isn't working for them. In most cases it is working; the full benefit simply hasn't arrived yet. The SURMOUNT-1 trial, which involved over 2,500 adults with obesity, recorded average body-weight reductions of around 20% at the 15mg dose over 72 weeks, a result that reflects cumulative effect over many months, not a rapid first-week response. SURMOUNT-1 is published in the New England Journal of Medicine for anyone who wants to read the data directly.
The practical implication: if you're in weeks one to four, give the process time. Your prescriber is managing titration for a reason.
This is a question our prescribers hear regularly, and it has several honest answers. First, some people adapt to a given dose after six to eight weeks, hunger creeps back, meals feel less restricted. This is one reason the titration schedule exists; a dose increase typically restores the effect. Second, diet composition matters more than people expect. A high-carbohydrate or very low-protein intake can blunt satiety signals even on tirzepatide. Our guide to eating on Mounjaro covers the practical adjustments that tend to help.
Third, there are people for whom appetite suppression is genuinely limited at a given dose, and if you are finding no appetite suppression on Mounjaro, our page on that experience goes through the most common reasons and what to do next. Separately, if Mounjaro is not suppressing your appetite as expected, we explain the factors most likely to be involved and how to address them. It's also worth noting that weight loss on tirzepatide isn't driven by appetite suppression alone, changes in how the body handles fat and blood sugar also play a role, which is explored on our page about whether Mounjaro burns fat or simply reduces appetite.
Tirzepatide has a half-life of around five days, which means active drug levels stay relatively stable across the week rather than spiking and crashing. Most people pick a consistent injection day, some find Sunday morning works well, others prefer to do it just before bed on whichever day fits their routine, pen pulled from the fridge door, cap off, done. The evidence doesn't strongly favour any particular time of day for appetite effects specifically, though injecting consistently on the same day each week keeps levels steadier.
What does matter is the injection site and technique: rotating between abdomen, thigh, and upper arm helps absorption stay consistent. For full detail on injection timing, storage, and missed-dose guidance, the prescriber and the Patient Information Leaflet are the right sources, those instructions are individualised in a way this page can't be.
If you're considering whether tirzepatide might suit you, or you're wondering how your current experience compares to what's expected, speaking to our prescribers is a straightforward starting point. Every consultation is reviewed by a GPhC-registered Independent Prescriber, not software, and there's no charge for the assessment itself.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.